Clinical Trial Update: A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial of tivozanib and erlotinib for metastatic non-small cell lung cancer, assigned by VeriStrat serum proteomic evaluation, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Tivozanib (tivozanib)

Snippet

Sponsor: University of Utah | Conditions: Non-small Cell Lung Cancer, Stage IV Disease | Phase 1, Phase 2 | Status: WITHDRAWN